Bleakley Financial Group LLC Makes New $33,000 Investment in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Bleakley Financial Group LLC purchased a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) in the third quarter, Holdings Channel.com reports. The firm purchased 80,000 shares of the company’s stock, valued at approximately $33,000.

Separately, Virtu Financial LLC purchased a new stake in shares of Unicycive Therapeutics in the 1st quarter valued at about $36,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a research note on Wednesday, October 9th. Brookline Capital Management raised Unicycive Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 9th. Finally, Benchmark reissued a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Price Performance

NASDAQ UNCY opened at $0.42 on Friday. Unicycive Therapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $1.82. The company has a market capitalization of $39.41 million, a P/E ratio of -0.40 and a beta of 2.36. The business has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.63.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.08. On average, research analysts expect that Unicycive Therapeutics, Inc. will post -0.26 earnings per share for the current fiscal year.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.